



P & T COMMITTEE MEETING

Agenda

April 8, 2014

1:00 pm – 5:00 p.m.

225 E. 16th Avenue, 1st Floor Conference Room, Denver, Colorado

Unfinished Business and General Orders

1. Approval of minutes from the January 7, 2013 P&T Meeting
2. Update on Insulins
3. Update on Alzheimers agents
4. Update on Atypical Antipsychotics
5. Update on Growth Hormones
6. Update on Intranasal corticosteroids
7. Update on Leukotriene modifiers
8. Update on Multiple Sclerosis agents
9. Update on Ophthalmic allergy agents
10. Update on Sedative/Hypnotics (non-benzodiazepine)
11. Update on Statins/Statin combinations

New Business

Global Prior Authorization Discussion

Drug Classes Up for Review:

- Testosterone Products
- Newer generation antihistamines and antihistamine decongestant combinations
- Angiotensin receptor blockers and combinations
- Renin inhibitors and combinations
- Fibromyalgia agents
- Long acting oral opioids
- Inhaled anticholinergics and combinations
- Inhaled Beta 2 agonists
- Long acting inhaled Beta 2 agonists
- Inhaled corticosteroids and combinations
- Skeletal muscle relaxants

- Topical immunomodulators

Each Review will contain:

- Drug class Overview and Agents up for review for each Drug Class
- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

Upcoming Meeting Date: Tuesday, July 8, 2014; 1:00 p.m. – 5:00 p.m.

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Swaniece Grubb at 303-866-3614 or by email at Swaniece.grubb@state.co.us. Written public comments can be submitted to pdl@state.co.us and will be distributed to all present P&T Committee Members.